Based on available Phase 2 trial data, the side effect profile of retatrutide shares similarities with other GLP-1 receptor agonists, as reflected in the Summary of Product Characteristics (SmPC) for approved agents such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro)
[1] [3] Given that obesity is itself a major cardiovascular risk factor, significant weight loss is generally associated with improvements in blood pressure, lipid profiles, and markers of systemic inflammation, all of which may benefit heart health
The included studies showed notable geographical diversity, with the majority originating from Europe and Asia
Weight loss accelerates weeks 12-24 (fastest period)
Luckily there are regulatory bodies that MLMs fall under
Using incorrect terminology or attempting conversions without proper guidance significantly increases the risk of medication errors, including potentially dangerous overdoses